Lexaria Bioscience (LEXX) Non Operating Investment Income (2018 - 2025)

Lexaria Bioscience has reported Non Operating Investment Income for 8 years, with the latest figure at -$22093.0 in Q4 2025.

• Quarterly Non Operating Investment Income fell 38.67% year-over-year to -$22093.0 in Q4 2025, while the trailing twelve-month figure through May 2026 was -$33540.0 (down 162.71% YoY) and the FY2025 annual result came in at -$33714.0, up 51.72% from the prior year.
• Non Operating Investment Income retreated to -$22093.0 in Q4 2025 per LEXX's latest filing, from -$11447.0 in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $34040.0 in Q1 2025 and troughed at -$143918.0 in Q3 2023.
• A 5-year average of -$27764.1 and a median of -$19012.5 in 2024 frame the typical range for Non Operating Investment Income.
• The sharpest annual moves came in 2021 and 2024: Non Operating Investment Income tumbled 4307.73% in 2021, then jumped 862.51% in 2024.
• Over 5 years, Non Operating Investment Income stood at -$41362.0 in 2021, then slumped by 87.68% to -$77628.0 in 2022, then soared by 31.45% to -$53215.0 in 2023, then jumped by 70.06% to -$15932.0 in 2024, then plunged by 38.67% to -$22093.0 in 2025.
• According to Business Quant data, Non Operating Investment Income over the past three periods registered -$22093.0, -$11447.0, and -$40375.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.